Lucius Larotrectinib – Buy Online
Lucius Larotrectinib – Buy Online
Lucius Larotrectinib – Buy Online

Lucius Larotrectinib – Buy Online

MYR 736.66

1,400+ terjual
Harga Promosi

Farmasi fizikal Hong Kong dengan jaminan produk tulen 100%

Sorotan Produk

In 2018, the FDA approved larotrectinib in the United States for tumors driven by NTRK1, NTRK2, or NTRK3 gene fusions. Use only as directed by a physician.

Jaminan Perkhidmatan

Penghantaran Rentas SempadanFarmasi BerlesenDisemak Ahli FarmasiJaminan Ketulenan

Spesifikasi

Spesifikasi
100mg*30 capsules
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong

10000 in stock

Category: Brand:

Maklumat Produk

Nama Inggeris
Larotrectinib
Nama Generik
Larotrectinib

Spesifikasi

Spesifikasi
100mg*30 capsules
Pengilang
Lucius Pharmaceuticals
Penghantaran
Hong Kong

Butiran Penuh

Indikasi

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Mekanisme Tindakan

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Farmakologi

12.1 Mekanisme Tindakan (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Dos dan Cara Penggunaan

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Langkah Berjaga-jaga

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Interaksi Ubat

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dos dan Cara Penggunaan(2.5)] CYP3A4 ， ， [ Dos dan Cara Penggunaan(2.5)]

Kesan Sampingan

Description [ Langkah Berjaga-jaga(5.1)] [ Langkah Berjaga-jaga(5.2)] [ Langkah Berjaga-jaga(5.3)] 6.1 ， ， ， Langkah Berjaga-jaga 444 VITRAKVI ， 62% 6 ，44% ……

Penyimpanan

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Package Insert

Ingredients

11 VITRAKVI C₂₁H₂₄F₂N₆O₆S， 526.51 g/mol， 428.44 g/mol (3S)-N-{5-[(2R)-2-(2,5- )-1- ] [1,5-a] -3- }-3- -1- ，

Indications

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Dos dan Cara Penggunaan

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Kesan Sampingan

Description [ Langkah Berjaga-jaga(5.1)] [ Langkah Berjaga-jaga(5.2)] [ Langkah Berjaga-jaga(5.3)] 6.1 ， ， ， Langkah Berjaga-jaga 444 VITRAKVI ， 62% 6 ，44% ……

Precautions

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Use in Pregnancy and Lactation

8.1 ， TRK ， Mekanisme Tindakan[ (12.1)]，VITRAKVI VITRAKVI ， ， ， 100 mg 11 0.7 ， ，

Interaksi Ubat

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dos dan Cara Penggunaan(2.5)] CYP3A4 ， ， [ Dos dan Cara Penggunaan(2.5)]

Clinical Pharmacology

12 12.1 Mekanisme Tindakan (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3 TRK ， ，

Clinical Studies

14 VITRAKVI ， NTRK LOXO-TRK-14001 (NCT02122913) SCOUT (NCT02637687) NAVIGATE (NCT02576431) ， ， VITRAKVI 100 mg， 18 VITRAKVI 100 mg/m²， ， 100 mg NTRK

Penyimpanan

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Ulasan Produk (15)

Filter: All Reviews
4.8★★★★★
+o***e· 3周前
★★★★
+t***3· 1个月前
Pembelian Disahkan
★★★★★

Penerangan produk

Indikasi

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Mekanisme Tindakan

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Farmakologi

12.1 Mekanisme Tindakan (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Dos dan Cara Penggunaan

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Langkah Berjaga-jaga

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Interaksi Ubat

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Dos dan Cara Penggunaan(2.5)] CYP3A4 ， ， [ Dos dan Cara Penggunaan(2.5)]

Kesan Sampingan

Description [ Langkah Berjaga-jaga(5.1)] [ Langkah Berjaga-jaga(5.2)] [ Langkah Berjaga-jaga(5.3)] 6.1 ， ， ， Langkah Berjaga-jaga 444 VITRAKVI ， 62% 6 ，44% ……

Penyimpanan

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F